VanEck Associates’s Impax Laboratories, Inc. IPXL Stock Holding History

VanEck Associates’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-893	Closed	-$12K	–	917
2016 Q4	$12K	Buy	893 +441	+98%	+$7.54K	﹤0.01%	878
2016 Q3	$11K	Sell	452 -208	-32%	-$5.59K	﹤0.01%	858
2016 Q2	$19K	Buy	660 +63	+11%	+$2.05K	﹤0.01%	831
2016 Q1	$19K	Buy	+597	New	+$21K	﹤0.01%	806

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

VanEck Associates's IPXL Position: Q1 2017 in Review

VanEck Associates sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 893 shares — an estimated $12K sold.

VanEck Associates first reported a position in IPXL in Q1 2016 and held it in 4 quarters. The position peaked at $19K in Q2 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

VanEck Associates reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
VanEck Associates sold 893 Impax Laboratories, Inc. shares in Q1 2017, an estimated $12K.
VanEck Associates first reported a position in Impax Laboratories, Inc. in Q1 2016 and held it in 4 quarters.
VanEck Associates's Impax Laboratories, Inc. position peaked at $19K in Q2 2016.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on VanEck Associates's 13F filing for Q1 2017, filed 11 May 2017.